Welcome to our dedicated page for Moss Genomics news (Ticker: MSSGF), a resource for investors and traders seeking the latest updates and insights on Moss Genomics stock.
Moss Genomics Inc. (MSSGF) features in news coverage that reflects its position at the intersection of biotechnology, genomics, blockchain infrastructure, and digital asset strategies. Company announcements describe Moss as a biotechnology and technology company focused on genomics and microbiome research, user-controlled genomic data platforms, and the use of blockchain to enhance security and privacy.
News updates highlight product developments such as the public launch of Perennial, a consumer-focused genomics platform that allows users to upload standard blood test results and receive personalized biomarker insights. Coverage also includes information on Moss’s plans for a secure, user-controlled genomic data vault built on Ethereum-based infrastructure, enabling individuals to vault their DNA, manage access permissions, and participate in research monetization opportunities.
Another recurring theme in Moss Genomics news is its digital asset and blockchain activity. Articles report on the company’s Ethereum treasury strategy, including acquisitions of ETH through private placements and contributions of ETH to on-chain contracts. News also covers Moss’s first operation in the Bitcoin ecosystem, where it mined a block on the Bitcoin Cash (BCH) blockchain using proprietary mining infrastructure.
Capital markets and corporate developments appear frequently as well, including listings on multiple exchanges and private placement financings used for working capital and digital asset accumulation. Readers following Moss Genomics news can expect updates on genomics product launches, blockchain integration efforts, digital asset treasury activities, strategic investments such as the proposed non-controlling stake in Genomes.io, and disclosures about risks associated with blockchain and cryptocurrency markets.
Moss Genomics (OTCQB:MSSGF) reported it mined a Bitcoin Cash block, marking its first operation in the Bitcoin ecosystem. BCH block #931,986 was mined on Jan 1, 2026 with miner ID "MOSS" in the coinbase signature.
The company said this milestone supports its stated goal to build long-term in the Bitcoin ecosystem and to align operating business with treasury strategy.
Moss Genomics (OTCQB: MSSGF) announced on November 11, 2025 the closing of a non-brokered private placement of 555,555 common shares at $0.18 per share for gross proceeds of $100,000.
Also effective November 11, 2025, Moss issued 5,164,213 common shares at a deemed price of $0.18 per share as consideration under asset purchase agreements (aggregate deemed consideration $966,435) to acquire approximately 224.7523 ETH at an average price of $3,833 per ETH. Following these transactions, Moss has 63,414,545 common shares outstanding. All securities are subject to applicable Canadian statutory hold periods.
An Annual and Special General Meeting is scheduled for November 13, 2025 to be held virtually; meeting materials and access instructions are posted on the company's website.
Moss Genomics (OTCQB: MSSGF) has announced progress in its Ethereum Treasury Strategy, contributing 200 ETH with a commitment for an additional 800 ETH to the STRAT presale. STRAT is an on-chain smart contract platform for ETH-based capital flows.
The company is advancing its blockchain integration strategy, following a previously announced non-binding term sheet for investment in Genomes.io, a genomics platform focused on decentralized data storage and patient privacy. The STRAT presale aims to raise 6,900 ETH from strategic investors. Moss also noted ongoing progress toward completing its February 2025 private placement financing.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) has announced two significant developments: the public launch of its genomics platform 'Perennial' and the closure of a cryptocurrency financing round.
The Perennial platform, which completed beta testing in March, enables users to upload standard blood test results and receive personalized biomarker-based health insights. The platform is now accessible at app.mossgenomics.com.
Additionally, the company has secured 130 ETH (Ethereum) at CAD $3,500 per ETH as part of its ongoing private placement, raising gross proceeds of CAD $455,000. In exchange, Moss issued 2,527,777 common shares at CAD $0.18 per share. The securities are subject to a four-month plus one-day statutory hold period.
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) has announced its listing on the OTC Markets under the ticker MSSGF. This strategic move aims to enhance share liquidity and increase accessibility for U.S.-based investors by enabling trading through U.S. broker-dealers.
The company, focused on biotechnology, is developing next-generation genomics products for personal health data management. Their current project includes testing a beta version of Perennial, a consumer platform that provides personalized health insights from blood test results based on key biomarkers.
Moss Genomics will maintain its listings on the Canadian Securities Exchange (CSE: MOSS) and Frankfurt Stock Exchange (FSE: F73).